抑制腺素再吸收可以通过腺素A2a受体减少糖尿病诱导的淋巴细胞过
Patrik Persson1, Angelica Fasching1, Liselotte Pihl1
1Division of Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
概括
增强的腺信号正常化糖尿病诱导的球过. 通过腺A2a受体,用迪拉泽普抑制腺的再吸收,降低了糖尿病大鼠的高球过率.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病与功能早期变化有关,包括球过.
- 减少腺A2a受体的信号传递与糖尿病诱导的球过的发展有关.
研究的目的:
- 在糖尿病病中研究增强内源性腺信号传递的治疗潜力.
- 为了检查抑制细胞腺再吸收对膜过率和糖尿病大鼠模型中的脏血流的影响.
主要方法:
- 在雄性斯普拉格-道利大鼠中,使用链毒素诱导胰岛素缺血性糖尿病.
- 评估了功能,包括膜过率和脏血流.
- 腺再吸收抑制剂迪拉泽普是通过内注射的,有或没有腺A2a抗剂ZM241385.
主要成果:
- 与对照组相比,糖尿病大鼠表现出增加的淋巴膜过率.
- 在糖尿病大鼠中,迪拉泽普的剂量依赖性降低了淋巴细胞过率,使其正常化至对照水平.
- 这些效应是由腺A2a受体激活的介导,由ZM241385.5的阻塞证实.
结论:
- 通过抑制腺再吸收来增强内腺信号传递,可以使糖尿病诱导的球过正常化.
- 氨酸A2a受体激活在调解迪拉泽普对糖尿病患者功能保护作用方面发挥着至关重要的作用.
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Antihypertensive Drugs: Direct Renin Inhibitors
687
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
687
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
888
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
888
Antihypertensive Drugs: Action of Diuretics
813
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
813
Antihypertensive Drugs: Angiotensin II Receptor Blockers
782
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
782
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
692
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
692


